Liposomes Market report by 78398

LIPOSOMES MARKET SIZE Scope of the Study This market insight report on Liposomes gives an insight into global Liposomes market. The report provides market analytics by application, and by therapeutic area. The market is divided by Application into Therapeutic, Cosmetic and Other; and by Therapeutics into Antifungal, Anticancer, Ophthalmic and Other. The study also provides information regarding products and technologies in the field of Liposomes. Business profiles of 46 major companies are discussed in the report. The report covers more than 330 companies that are engaged in Liposomes research and supply of products and/or services. Compilation of Worldwide Patents and Research related to Liposomes is also provided. Projections and estimates are also illustrated by geographic regions encompassing North America, Europe, Asia-Pacific, and Rest of World with 97 exclusive graphically represented exhibits. Information related to recent product releases, product developments, partnerships, collaborations, mergers and acquisitions, and other areas of concern is also covered in the report. Liposomes’ report is an ideal research tool providing strategic business intelligence to the corporate sector. This report may help strategists, investors, laboratories, pharmaceutical companies, contract research organizations, biotechnology companies and drug approval authorities in- Gauging Competitive Intelligence  Identifying Key Growth Areas and Opportunities  Understanding Geographic Relevance to Product  Knowing Regional Market Sizes and Growth Opportunities and Restraints  Keeping Tab on Emerging Technologies  Equity Analysis  Tapping New Markets

Analytics and data presented in this report pertain to several parameters such as –  Global and Regional Market Sizes, Market Shares, Market Trends  Product (Global and Regional) Market Sizes, Market Shares, Market Trends  Technology Trends  Corporate Intelligence  Key Companies by Sales, Brands, Products  Consumer Behavioral Patterns

RITMIR028: Liposomes – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com

Sample Page - 1

 Other Strategic Business Affecting Data

Research Methodology RI Technologies publishes business intelligence reports by going through a cycle of diligent research and analysis activity. Research is done using both online and offline resources. The study outline of this report is sketched on the following lines – global market analysis, regional market analysis, product segmentation, global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape, technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is also helpful for doing market evaluations, and estimating the market size for the future.

This report is uniquely researched and the methodology includes:  Need and Scope of Study  Product Definitions  Segmental Analysis  Regional Analysis  Exclusive Data Analytics  Corporate Intelligence  Feedback

Right from concept to final compilation of this report, both primary and secondary research methods are applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the information for authentication of our own findings. Secondary research includes government publications, investment research reports, web based surveys, website information of both companies and markets, and other offline resources such as print publications and CDs. Our compilation of easy to navigate PDF reports are essential value addition resources for leading and growing companies.

RITMIR028: Liposomes – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com

Sample Page - 2

II - REPORT SYNOPSIS Liposomes are nano sized artificial vesicles of spherical shape composed of a bilayer membrane that can be produced from natural phospholipids and cholesterol. Liposomes are composed of naturally-derived phospholipids which when combined with water immediately forms a bi-layered sphere. Liposomes contain a core of aqueous material; lipid spheres that contain no aqueous material are called micelles, The size of these spheres is very small, in the order of a nanometer. Because of the small size of the phospholipid molecule and microspheres, they can pass through the epidermis and act as a carrier for the enclosed substances. Liposomes also comprise small deposits that may contain an antibiotic, antigen, allergen, drug substance or even a gene. Liposomes are capable of entering the body without causing an immune rejection or hypersensitivity reaction.

Segmentation of Liposomes Market Exhibit 1. Segmentation of Global Liposomes Market by Application Application Therapeutic Cosmetic Other* © RIT, 2013

* Includes Agro-Food, Paints (Water Based, Resins, Self Healing Paints), Neutraceuticals, and Diagnostics

Liposomal Formulations Used in Medical Practice Liposomes belong to the class of nanosized unilamellar phospholipid bilayer vesicles. These are considered as the most promising and comprehensively studied drug delivery vehicles. The applications of the Liposome-formulated drugs have enhanced over the years and they are now part of the cancer treatment and systemic or local fungal infections. The unique feature of the Liposome-formulated drugs to remain biologically inert, biocompatible and restricting the cause of unwanted toxic or antigenic reactions have helped it maintain a high level of popularity in the field of drug research. The horizon and application of Liposomes have enormously undergone transformations owing to its use in the treatment of solid tumors. The tumors are targetted with Liposomes containing bisphosphonate which reduces the tumor associated macrophages. The Other important developments like use of genetic components as therapeutic molecules are the advancements in the field of delivery systems have further enhanced the scope of Liposomes based therapy. The components of Liposomes present in the lipid-DNA complexes commonly called lipoplexes, combat with the viral gene transfection systems. The excellent flexibility, applicability and the enormous properties of Liposomal formulations are expected to remain as the emerging drug delivery resources.

RITMIR028: Liposomes – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com

Sample Page - 3

Segmentation of Liposomes Market by Therapeutic Application Global Liposomal Therapeutic market is segmented by therapeutic area into Antifungal, Anticancer, Ophthalmic and Other. Exhibit 2. Segmentation by Therapeutic Application Therapeutic Antifungal Anticancer Ophthalmic Other* © RIT, 2013

*Includes vaccines (Influenza, Hepatitis), Prostaglandins, Antimalarials, Cardiovascular Diseases, Dermatology, Analgesics

RITMIR028: Liposomes – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com

Sample Page - 4

Global Market Analysis Exhibit 3. Liposomes– Global Market Estimations and Predictions (2005 – 2020) in US$ Billion Year

Value

2005

XX.XX

2006

XX.XX

2007

XX.XX

2008

XX.XX

2009

XX.XX

2010

XX.XX

2011

XX.XX

2012

XX.XX

2013

XX.XX

2014

XX.XX

2015

XX.XX

2016

XX.XX

2017

XX.XX

2018

XX.XX

2019

XX.XX

2020

XX.XX

CAGR %

XX.XX

US$ Billion

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

RITMIR028: Liposomes – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com

Sample Page - 5

III. MARKET DYNAMICS Liposomes and Pharmaceuticals Cosmeceutical and pharmaceutical markets today boast a wide range of topical products that have many active ingredients. A common ingredient in many topical application creams and lotions are liposomes that act as a protective mechanism while also moisturizing the skin. These liposomes are nothing but spherical vesicles that comprise phospholipids having an aqueous core and contain lipophilic or hydrophilic active ingredients. Depending on their properties, these dermal applications can penetrate into the skin to carry these actives to the target site where the molecules get released. Liposomes have improved the efficiency of many such dermal applications by improving their level of penetration into the skin. They were first used by cosmetic giant Christian Dior in 1986 in a product named Capture. However, today the use of nanotechnology in cosmetics is under consideration and therefore it is important to understand the strength of this new delivery technology. The use of liposomes in pharmaceutical products is largely for Parenteral and therefore systemic applications. Typical examples of liposomes in pharmaceutical products are Lipofundin™ developed by Braun Melsungen, Intralipid™ by Kabi Pharmacia and Arikace™ a liposomally encapsulated Amikacin prescribed for lung disease. The lipid that is generally used to make these liposomes is phsophatidylcholine that forms a part of the cell membrane and is therefore not hazardous. Liposomal cosmetics that contain phospholipids with a flexible membrane are made of biodegradable material, for example ROVISOME®.

Liposomes and Nanotechnology ROVISOME® is a flexible liposome that has unilamellar vesicles of very small size (approximately 50-400 nm) and comprises more than 80% of soybean phosphatidylcholine and a large amount of linoleic acid as well. This type of liposomes provides the skin with essential polyunsaturated fatty acids or vitamin F that facilitate ceramide 1 formation and with choline that forms a component of NMF or natural moisturizing factor. In an experimental study that was carried out, liposomes also exhibited other properties such as reduction in wrinkles and also improving the smoothness of the skin. They also exhibited pharmaceutical properties such as reducing efflorescences in the treatment of acne. In-vivo and ex-vivo studies have also shown liposomes to have the ability to penetrate the skin. In addition the encapsulation and delivery of hydrophilic and lipophilic actives of differing molecular sizes increases the bioavailability thereby improving the effectiveness of the final product that is also inexpensive.

RITMIR028: Liposomes – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com

Sample Page - 6

Analysis by Application Exhibit 4. Liposomal Applications– Global Market Estimations and Predictions (2005 – 2020) for Therapeutic, Cosmetic and Other in US$ Billion Year/Application

Liposomal Therapeutics

Cosmetics

Others

Total

2005

XX.XX

2006

XX.XX

2007

XX.XX

2008

XX.XX

2009

XX.XX

2010

XX.XX

2011

XX.XX

2012

XX.XX

2013

XX.XX

2014

XX.XX

2015

XX.XX

2016

XX.XX

2017

XX.XX

2018

XX.XX

2019

XX.XX

2020

XX.XX

CAGR %

XX.XX

US$ Billion

2005

2006

2007

2008

2009

2010

Liposomal Therapeutics

2011

2012

2013

2014

2015

2016

Cosmetics

RITMIR028: Liposomes – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com

2017

2018

2019

2020

Others

Sample Page - 7

Analysis by Liposomal Therapeutic Applications Exhibit 5. Liposomal Ophthalmic Therapeutics – Global Market Estimations and Predictions (2005 – 2020) by Geographic Region for North America, Europe, Asia-Pacific, and Rest of World in US$ Million Year/Region

North America

Europe

Asia-Pacific

Rest of World

Total

2005

XX.XX

2006

XX.XX

2007

XX.XX

2008

XX.XX

2009

XX.XX

2010

XX.XX

2011

XX.XX

2012

XX.XX

2013

XX.XX

2014

XX.XX

2015

XX.XX

2016

XX.XX

2017

XX.XX

2018

XX.XX

2019

XX.XX

2020

XX.XX

CAGR %

XX.XX

US$ Million

2005

2006

2007

2008

North America

2009

2010

2011

Europe

2012

2013

2014

2015

2016

Asia-Pacific

RITMIR028: Liposomes – A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com

2017

2018

2019

2020

Rest of World

Sample Page - 8

Pharmaceutical Market Armed with Liposomes to Combat Fungal Infections Globally , the instances of fungal infections are on the rise , especially in cases of people who are immunocompromised. Immunocompromised people are incapable of developing a normal immune response, usually as a result of disease, malnutrition, or immunosuppressive therapy. Also, there is no decline in the count of AIDS and cancer patients. So the experts in this field are perturbed. The therapy and diagnosis of fungal infections are implicitly arduous and demanding, especially to those more liable to opportunistic infections. Opportunistic infection is an infection by a microorganism that normally does not cause disease but becomes pathogenic when the body's immune system is impaired and unable to fight off infection. Till today the sales output of Amphocil is at a slow pace, but Abelcet is the foremost to get certified in the United States. In November 1995, the FDA certified the drug to be harmless and is capable of causing the intended effect in curing aspergillosis in patients who cannot withstand or are refractory to amphotericin B. The initial sale output of company was declared to be $6 million. Market experts were expecting certifications from FDA for by year 1996 ending for Amphotec and by year 1997 for AmBisome. All the three drugs are expected to have the same effect as expressed by some experts like Walsh and Edward Hurwitz, an analyst with Robertson, Stephens & Co., Only the marketing strategy and price elements will be the determining elements. Exhibit 6. List of Liposomal Therapeutics S. No.

Product

Clearance Details

Developer

Country

Year

Approval Reason

AmBisome (liposomal amphotericin B)

NexStar Pharmaceuticals, Inc

Ireland

1989

Treatment of refractory fungal infections

Amphocil (amphotericin B colloidal dispersion)

Sequus Pharmaceuticals, Inc.,

United Kingdom

1994

Same indication as first

Abelcet (amphotericin B lipid complex)

The Liposome Company's

1995

first-line therapy in the treatment of AIDS-related cryptoccocal meningitis and systemic cryptococcosis

More….. © RIT, 2013

Exhibit 7. List of Global Major Companies S. No

Company

Region

Website

Advanced Biomedical Ltd.

www.advanced-biomedical.co.uk

Arboretum Skincare

USA

www.arboretum-skincare.com

Avanti Polar Lipids, Inc.

USA

www.avantilipids.com

Azaya Therapeutics, Inc.

USA

www.azayatherapeutics.com

BioZone Laboratories, Inc.

USA

www.biozonelabs.com

Luye Pharma Group Ltd.

China

www.luye.cn

SurModics Pharmaceuticals

USA

www.surmodicspharma.com

Sample Page - 9

LIPOSOMES – THE OUTLOOK The market for liposomes presents attractive growth opportunities, driven by growing demand for increasingly effective drugs in the field of pharmaceuticals, and niche applications in other emerging areas. Liposome drug delivery systems have been instrumental in the formulation of potent drugs to enhance therapeutics. A majority of liposome formulations are designed to bring down toxicity. It is also in a limited way formulated enhance accumulation at the target site and rendered useful in several clinical applications. Presently pharmaceutical products of liposome-based therapeutics arise from a better understanding of lipid-drug interactions as well as liposome disposition mechanisms. Among these mechanisms are included the impeding of the fast clearance of liposomes. This is achieved by exercising control over surface hydration, charge and size. Liposomes are actually lipid vesicles that are derived from self-forming enclosed lipid bi-layers upon hydration. Increased protection and elevated efficaciousness are being accomplished for an extensive range of drug classes. These encompass gene therapeutics, vaccines, antimicrobials, antifungal, antiviral and anti-tumor agents. The comprehension that is acquired from clinical use of liposome drug delivery systems can presently be amalgamated for the design of liposomes that are targeted to tissues and cells. This could be with or without expression of target recognition molecules on liposome membranes. Continued improvements of bio-membrane sensors and liposome delivery systems that are competent in the association of other membrane-bound proteins in vivo could allow selective delivery of therapeutic compounds to chosen intracellular target areas. As large quantities of stable and cost-effective liposomes are manufactured, many new applications will surface. The novel applications could be self-healing paints, single tube two-component resins or glues and water-based paints…..

Sample Page - 10

IV. PRODUCT/TECHNOLOGY RESEARCH Liposomes are nano size artificial vesicles of spherical shape composed of a bilayer membrane that can be produced from natural phospholipids and cholesterol. Liposomes are composed of naturally-derived phospholipids which when combined with water immediately forms a bi-layered sphere. Liposomes contain a core of aqueous material; lipid spheres that contain no aqueous material are called micelles, In 1961, Dr Alec D. Bangham produced the first liposomes. He was studying the relationship between blood clotting and phospholipids. He observed that as soon as phospholipids came into contact with water, they assumed a spherical structure. Dr. Bangham also deciphered the cause for this transformation. He noticed that one end of the phospholipid molecule was water soluble, while the other end was not. Therefore, when water-soluble drugs were added to water, they were enclosed or trapped within the hydrophobic ends. The reverse was the case when fat-soluble medicaments were brought near phospholipids. Such drugs were trapped within the phospholipid layers. Liposomes are artificial vesicles that are made up of concentric bilayers of lipid that are separated by compartments of water. The bilayer forming lipids are amphiphilic in nature meaning they have a polar head group that is attached to one or maybe even two hydrophobic hydrocarbon tails. On exposure to an aqueous medium the hydrophilic heads interact with each other and Vender Waal’s interactions are also seen between the hydrocarbon chains. They also interact with water called hydrophilic interactions with a hydrophobic effect that then result in a spontaneous formation of bilayers that are closed. The size of these spheres is very small, in the order of a nanometer. Liposomes are of various sizes ranging from those having a diameter of 20nm to others that are visible under a light microscope with a diameter of 1 µm or bigger and similar in size to living cells. Because of the small size of the phospholipid molecule and microspheres, they can pass through the epidermis and act as a carrier for the enclosed substances. Liposomes are also different with respect to their lipid composition and structural organization based upon which they can be classified into unilamellar, multilamellar and oligolamellar vesicles. Liposomes have been made so that the solute can be surrounded by the aqueous compartment called polar solute or alternatively be embedded in the lipid bilayers known as lipophilic or amphiphilic solutes. Liposomes also comprise small deposits that may contain an antibiotic, antigen, allergen, drug substance or even a gene. Liposomes are capable of entering the body without causing an immune rejection or hypersensitivity reaction. Phospholipids arrange themselves so as to form a membrane having a wall of hydrophilic heads that would prevent permeation of oil droplets through it. It is also not possible for water to pass through the membrane due to the presence of lipophilic tails of the liposomes that do not allow passage of water. The only part of the membrane that allows passage of only certain chemicals into and out of the cell is special protein molecules that are programmed for the purpose.

The use of liposomes in biological and biochemical research are five-fold. They include: 

Lipid-Protein interactions



Membrane dynamics

Sample Page - 11



Delivery systems for biomolecules and small molecules into cells



Membrane related proteins



Regulation of protein function by lipids

Forms of Liposomes 1. Conventional forms of liposomes include 

Stabilized natural lecithin (PC) mixtures



Synthetic identical-chain phospholipids



Glycolipid containing liposomes

2. Special forms of liposomes are 

Bipolar fatty acid liposomes



Antibody directed liposomes



Methyl/ Methyane liposomes

3. x-linked liposomes 

Lipoprotein coated liposomes



Carbohydrate wated liposomes



Multiple encapsulated liposomes



Emulsion compatible liposomes

Conventional liposomes are man-made liposomes that can carry and deliver drugs that can also delay their elimination by the system. This in turn permits the drugs to stay in the bloodstream for prolonged period of time. These liposomes when heated to a specific temperature (40ºC to 42ºC), there occurs an opening in the liposomes thereby permitting its drug to released rapidly in the targeted area. Exhibit 8. List of Liposome based Drugs in Clinical Trials Trade Name

Indication

Company

Status

Liposomal alpha-TEA (α-TEA) (cyclosporine)

Rejection post lung transplantation, asthma & cancer

Alulim Pharma, Inc.

Preclinical

Liposomal Cyclosporine A (cyclosporine)

Rejection post lung transplantation, asthma & cancer

Alulim Pharma, Inc.

Preclinical

ATI-0918 (Liposomal encapsulation of doxorubicin)

Cancer

Azaya Therapeutics, Inc.

Preclinical

ATI-1123 (Liposomal formulation of docetaxel)

NSCLC, gastric cancer, pancreatic cancer, and softtissue sarcoma

Azaya Therapeutics, Inc.

Phase II

Thermodox (Doxorubicin)

Recurrent chest wall breast cancer

Celsion Corporation

Phase I/II

About RI Technologies RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly

Sample Page - 12

monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging technologies in areas of discovery, design and development.

Research – As Good as the Methodology is! 

Gauging Competitive Intelligence



Identifying Key Growth Areas and Opportunities



Understanding Geographic Relevance to Product



Knowing Regional Market Sizes and Growth Opportunities and Restraints



Keeping Tab on Emerging Technologies



Equity Analysis



Tapping New Markets

© COPYRIGHT The copyright and publication rights to all RI Technologies' reports and other products are the property of the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of the material without express permission is not allowed. The buyer, under no circumstances, shall license, resell or repackage, or sell data without prior permission of the company.

DISCLAIMER RI Technologies sells content in good faith. The company is not liable to the buyer for any implications arising out of the usage of data for any particular purpose. The company makes no representations or warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for data compilation and presentation, the company does not accept any responsibility for findings in the study which are a cumulative effort of primary and secondary research resources. The studies do not endorse or promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage of the data.

Sample Page - 13